Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acumen Pharmaceuticals Inc
(NQ:
ABOS
)
2.910
+0.100 (+3.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
175,122
Open
2.850
Bid (Size)
2.800 (25)
Ask (Size)
3.090 (10)
Prev. Close
2.810
Today's Range
2.810 - 2.950
52wk Range
1.810 - 6.370
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-31.21%
-31.21%
1 Month
-14.66%
-14.66%
3 Month
-10.46%
-10.46%
6 Month
-20.05%
-20.05%
1 Year
-53.81%
-53.81%
More News
Read More
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
August 06, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals's Earnings: A Preview
March 25, 2024
Via
Benzinga
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 11, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via
Talk Markets
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 14, 2024
Via
Benzinga
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
March 26, 2024
Via
InvestorPlace
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 26, 2024
March 26, 2024
Via
Benzinga
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
March 19, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
March 12, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
February 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.